在接受里法治疗的患者中优化塔克罗利斯治疗的挑战:一个案例系列
Jeroen P A Houwen1, Aurelia H M de Vries Schultink1, Bas J M Peters2
1Department of Clinical Pharmacy, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands.
British journal of clinical pharmacology
|September 30, 2025
概括
里法能显著改变移植患者的塔克罗利斯水平,需要仔细监测. 在开始,继续或停止使用里法时,剂量调整至关重要,以保持治疗性塔克罗利斯度.
科学领域:
- 药理学 药理学是指药理学的学科.
- 移植医学 移植医学
- 药物相互作用 药物相互作用
背景情况:
- 塔克罗利马斯是器官移植中的重要免疫抑制剂.
- 它有一个狭窄的治疗窗口,使精确的剂量至关重要.
- 药物相互作用可以显著影响塔克罗利斯的疗效和安全性.
研究的目的:
- 为了说明里法素对塔克罗利斯治疗的药理动力学影响.
- 为了突出塔克罗利斯代谢受到里法的影响的变异性.
- 为了强调治疗药物监测在里法的同时使用期间的重要性.
主要方法:
- 案例报告分析了两名移植接受者的情况.
- 在里法互动期间评估塔克罗利斯的药理动力学.
- 监测塔克罗利斯度和剂量调整.
主要成果:
- 利法的同时使用导致塔克罗利斯剂量要求大幅增加.
- 在使用里法时,度与剂量比率 (CDR) 显著下降.
- 停止使用利法导致塔克罗利斯水平延迟但明显增加,需要降低剂量.
结论:
- 里法素导致塔克罗利斯代谢的极端变化.
- 每日治疗药物监测在启动,继续或停止使用里法时至关重要.
- 如果可能的话,建议避免使用塔克罗利斯和里法的联合治疗.
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
201
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
201
Pulmonary Tuberculosis V
540
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
540
Pulmonary Tuberculosis I
838
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
838
Pharmacokinetics: Drug–Drug Interactions
361
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
361
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
256
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
256
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
214
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214


